香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Touyun Biotech Group Limited 透 雲 生 物 科 技 集 團 有 限 公 司 （於百慕達註冊成立的有限公司） （股份代號：1332） 根據上市規則第13.19條作出之公告 本 公 告 乃 由 透 雲 生 物 科 技 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.19條及證券及 期貨條例（ 香港法例第571章 ）第XIVA部內幕消息條文（ 定義見上市規則 ）而作出。 茲提述本公司於2025年6月30日及2025年9月30日就解決審計保留意見的行動計劃 執行情況季度更新（「季度更新」）所刊發之公告。 於2022年12月12日，本公司之間接全資附屬公司山西透雲生物科技有限公司（「借 款人」）與一名貸款人（ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 截至月份: 2025年11月30日 狀態: 新提交 公司名稱: 透雲生物科技集團有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01332 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 ...

Group 1 - The core point of the article highlights that Touyun Biotech (01332) experienced a significant stock price increase, rising over 80% during the trading session, with a current increase of 54.47% to HKD 0.38, and a trading volume of HKD 12.0568 million [1] - Recently, Touyun Biotech announced a strategic cooperation agreement involving its wholly-owned subsidiary, Shanxi Touyun, which will procure no less than RMB 1 billion worth of Rhodella and related products from a sales consortium during the period from 2026 to 2028 [1] - The company’s Rhodella product received a new usage license from the National Health Commission in November 2024, expanding its application range and entering markets for artificial fish, shrimp, and plant-based milk [1]

CEO Compensation - The total compensation for the CEO, Xia Yilin, for the year ended December 31, 2023, was HKD 16,000, while for 2022 it was HKD 3,102,000, indicating a significant decrease [3]. - The CEO's salary and allowances for 2023 were HKD 16,000 compared to HKD 3,084,000 in 2022, reflecting a drastic reduction [3]. - There were no contributions to the retirement plan for the CEO in 2023, while there were HKD 18,000 in contributions in 2022 [3].

Core Insights - The stock of Touyun Biological (01332.HK) experienced a significant increase of nearly 900% over the previous three trading days, indicating a strong market interest and volatility in its shares [2] - However, the stock price has seen a sharp decline of over 28% today, with a current drop of 22%, trading at HKD 0.39, reflecting a rapid reversal in investor sentiment [2] - The trading volume reached HKD 8.95 million, suggesting active trading despite the price drop [2]

Core Viewpoint - The stock price of Touyun Biotechnology (01332) experienced a significant increase of nearly 900% over the previous three trading days, followed by a sharp decline of over 28% today, currently trading at HKD 0.39 with a transaction volume of HKD 8.95 million [1] Group 1: Stock Performance - The maximum cumulative increase in stock price over the last three trading days was close to 900% [1] - Today's stock price has dropped by 22% as of the report, indicating a significant reversal in market sentiment [1] Group 2: Strategic Developments - Touyun Biotechnology announced an unusual fluctuation in stock price and trading volume [1] - A strategic cooperation agreement was signed on October 23 between its wholly-owned subsidiary, Shanxi Touyun, and several companies, including Shenzhen Building Supply Chain Technology, Henan Guozi Marketing Management, and Beijing Huanjia Biological Technology [1] - The agreement stipulates that from 2026 to 2028, the sales consortium will purchase no less than RMB 1 billion worth of Rhizoclonium and related products from Shanxi Touyun [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 透雲生物科技集團有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01332 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,500,000,000 | HKD | | 0.04 | HKD | | 500,000,000 ...

Core Viewpoint - The company has observed a significant increase in its share price and trading volume on specific dates in late October and early November 2025, but the board is unaware of any reasons for these changes or any undisclosed information that could affect the market [1] Group 1 - The board confirmed that the company's business operations remain normal and that there have been no significant changes in its financial condition as of the date of the announcement [1] - A wholly-owned subsidiary of the company, Shanxi Tuo Yun Biotechnology Co., Ltd., signed a strategic cooperation agreement on October 23, 2025, with three other companies for a procurement deal [1] - The strategic cooperation agreement involves a sales consortium purchasing no less than RMB 1 billion (approximately 140 million USD) worth of Rhizoclonium and related products from Shanxi Tuo Yun during the period from 2026 to 2028 [1]

Core Viewpoint - The company has observed an increase in share price and trading volume on specific dates in late October and early November 2025, but the board is unaware of any reasons for these changes or any undisclosed information that could affect the market [1] Group 1 - The board confirmed that the company's business operations remain normal and that there have been no significant changes in the business or financial status as of the announcement date [1] - A wholly-owned subsidiary, Shanxi Tuo Yun Biotechnology Co., Ltd., signed a strategic cooperation agreement on October 23, 2025, with three companies for a procurement deal valued at no less than RMB 1 billion for Rhizoclonium and related products from 2026 to 2028 [1] - The specific commercial terms such as pricing, quantity, and delivery methods are yet to be negotiated, and a formal procurement agreement has not been signed [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Touyun Biotech Group Limited 董事會欣然向本公司股東及潛在投資者提供業務更新：本公司之全資附屬公司山 西透雲生物科技有限公司（「山西透雲」）已於2025年10月23日與深圳樓宇間供應鏈 科技股份有限公司 、 河南國字頭營銷管理有限公司及北京合萬家生物科技有限公 司（ 統稱「銷售聯合體」）簽署一份戰略合作協議（「戰略合作協議」）。根據該戰略合 作協議，於2026年至2028年期間，銷售聯合體將向山西透雲採購總值不低於人民 – 1 – 幣10億元的萊茵衣藻及相關產品。具體商業條款如售價、數量及交付方式等須待 訂約各方進一步磋商，尚未簽署正式採購協議。此戰略合作協議屬本集團為其萊 茵衣藻產品系列探索市場機遇之日常業務運作的一部分。 由於該戰略合作協議所擬進行之交易可能會亦可能不會落實，本公司股東及潛在 投資者於買賣本 ...